Related Experiment Video
Updated: Jan 18, 2026

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
Published on: December 23, 2022
Novel Phenotypic Fluorescent Three-Dimensional Platforms for High-throughput Drug Screening and Personalized
Changge Fang1, Ingalill Avis, David Salomon
11. Advanced Personalized Diagnostics LLC, 6006 Bangor Drive, Alexandria, VA 22303, USA. ; 2. Angiogenesis Core Facility, Advanced Technology Center, Room 115, Center for Cancer Research, National Cancer Institute, 8717 Grovemont Circle, Bethesda, MD 20892-4605, USA.
Abstract:
We have developed novel phenotypic fluorescent three-dimensional co-culture platforms that efficiently and economically screen anti-angiogenic/anti-metastatic drugs on a high-throughput scale. Individual cell populations can be identified and isolated for protein/gene expression profiling studies and cellular movement/interactions can be tracked by time-lapse cinematography. More importantly, these platforms closely parallel the in vivo angiogenic and metastatic outcomes of a given tumor xenograft in the nude mouse model but, unlike in vivo models, our co-culture platforms produce comparable results in five to nine days. Potentially, by incorporating cancer patient biopsies, the co-culture platforms should greatly improve the effectiveness and efficiency of personalized chemotherapy.

